Inclusion body myositis: current pathogenetic concepts and diagnostic and therapeutic approaches

Lancet Neurology

Volumn 6, Issue 7, 2007, Pages 620-631

  Needham, Merrilee ^a   Mastaglia, Frank L ^a  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; ANTIOXIDANT; AZATHIOPRINE; BETA1A INTERFERON; CARNITINE; CLENBUTEROL; ETANERCEPT; IMMUNOGLOBULIN; METHOTREXATE; MYCOPHENOLIC ACID; OXANDROLONE; PLACEBO; PREDNISONE; THYMOCYTE ANTIBODY; UBIDECARENONE;

AGING; CLINICAL FEATURE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; DRUG MEGADOSE; DYSPHAGIA; ENVIRONMENTAL FACTOR; GENETIC SUSCEPTIBILITY; HEREDITY; HUMAN; INCLUSION BODY MYOSITIS; KINESIOTHERAPY; MUSCLE ATROPHY; MUSCLE BIOPSY; MUSCLE WEAKNESS; MYALGIA; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOGENESIS; PREVALENCE; PRIORITY JOURNAL; REVIEW; RISK FACTOR; TENDON TRANSFER;

HUMANS; MYOSITIS, INCLUSION BODY;

EID: 34250377470     PISSN: 14744422     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1474-4422(07)70171-0     Document Type: Review

References (153)

1. Chou S. Myxovirus-like structures in a case of human chronic polymyositis. Science 158 (1967) 1453-1455
2. Yunis E., and Samaha F. Inclusion body myositis. Lab Invest 25 (1971) 240-248
3. Mendell J., Sahenk Z., Gales T., and Paul L. Amyloid filaments in inclusion body myositis: novel findings provide insight into nature of filaments. Arch Neurol 48 (1991) 1229-1234
4. Amato A., Gronseth G., Jackson C., et al. Inclusion body myositis: clinical and pathological boundaries. Ann Neurol 40 (1996) 581-586
5. Badrising U., Maat-Schieman M., van Duinen S., et al. Epidemiology of inclusion body myositis in the Netherlands: a nationwide study. Neurology 55 (2000) 1385-1387
6. Phillips B., Zilko P., and Mastaglia F. Prevalence of sporadic inclusion body myositis in Western Australia. Muscle Nerve 23 (2000) 970-972
7. Dabby R., Lange D., Trojaborg W., et al. Inclusion body myositis mimicking motor neuron disease. Arch Neurol 58 (2001) 1253-1256
8. Askanas V., and Engel W. Inclusion body myositis: a myodegenerative conformational disorder associated with Aβ, protein misfolding, and proteasome inhibition. Neurology 66 (2006) S39-S48
9. Dalakas M. Sporadic inclusion body myositis-diagnosis, pathogenesis, and therapeutic strategies. Nat Clin Pract 2 (2006) 437-445
10. Shamim E., Rider L., Pandey J., et al. Differences in idiopathic inflammatory myopathy phenotypes and genotypes between Mesoamerican Mestizos and North American caucasians: ethnogeographic influences in the genetics and clinical expression of myositis. Arthritis Rheum 46 (2002) 1885-1893
11. Felice K., and North W. Inclusion body myositis in Connecticut: observations in 35 patients during an 8-year period. Medicine 80 (2001) 320-327
12. Garlepp M., Laing B., Zilko P., Ollier W., and Mastaglia F. HLA associations with inclusion body myositis. Clin Exp Immunol 98 (1994) 40-45
13. Badrising U., Schreuder G., Giphart M., et al. Associations with autoimmune disorders and HLA class I and II antigens in inclusion body myositis. Neurology 63 (2004) 2396-2398
14. Lampe J., Gossrau G., Kempe A., et al. Analysis of HLA class I and II alleles in sporadic inclusion-body myositis. J Neurol 250 (2003) 1313-1317
15. Koffman B., Sivakumar K., Simonis T., Stroncek D., and Dalakas M. HLA allele distribution distinguishes sporadic inclusion body myositis from hereditary inclusion body myopathies. J Neuroimmunol 84 (1998) 139-142
16. Love L., Leff R., Fraser D., et al. A new approach to the classification of idiopathic inflammatory myopathy: myositis-specific autoantibodies define useful homogeneous patient groups. Medicine 70 (1991) 360-374
17. Price P., Santoso L., Mastaglia F., et al. Two major histocompatibility complex haplotypes influence susceptibility to sporadic inclusion body myositis: critical evaluation of an association with HLA-DR3. Tissue Antigens 64 (2004) 575-580
18. Scott A., Allcock R., Mastaglia F., Nishino I., Nonaka I., and Laing N. Sporadic inclusion body myositis in Japanese is associated with the MHC ancestral haplotype 52.1. Neuromuscul Disord 16 (2006) 311-315
19. O'Hanlon T., Carrick D., Arnett F., et al. Immunogenetic risk and protective factors for the idiopathic inflammatory myopathies: distinct HLA-A, -B, -Cw, -CRB1 and -DQA1 allelic. Medicine 84 (2005) 338-349
20. Amato A., and Shebert R. Inclusion body myositis in twins. Neurology 51 (1998) 598-600
21. Hengstman G., van Engelen B., ter Laak H., and Gabreels-Festen A. Familial inclusion body myositis with histologically confirmed sensorimotor axonal neuropathy. J Neurol 247 (2000) 882-884
22. Sivakumar K., Semino-Mora C., and Dalakas M. An inflammatory, familial, inclusion body myositis with autoimmune features and a phenotype identical to sporadic inclusion body myositis: studies in three families. Brain 120 (1997) 653-661
23. Mastaglia F., Price P., Walters S., Fabian V., Miller J., and Zilko P. Familial inclusion body myositis in a mother and son with different ancestral MHC haplotypes. Neuromuscul Disord 16 (2006) 754-758
24. Askanas V., and Engel W. New advances in inclusion body myositis. Curr Opin Rheumatol 5 (1993) 732-741
25. Argov Z., and Yarom R. Rimmed vacuole myopathy sparing the quadriceps: a unique disorder in Iranian Jews. Neurol Sci 64 (1984) 33-43
26. Nishino I., Noguchi S., Murayama K., et al. Distal myopathy with rimmed vacuoles is allelic to hereditary inclusion body myopathy. Neurology 59 (2002) 1689-1693
27. Vasconcelos O., Raju R., and Dalakas M. GNE mutations in an American family with quadriceps-sparing IBM and lack of mutations in sIBM. Neurology 59 (2002) 1776-1779
28. Orth M., Tabrizi S., and Schapira A. Sporadic inclusion body myositis not linked to prion protein codon 129 methionine homozygosity. Neurology 55 (2000) 1235
29. Sivakumar K., Cervenakova L., Dalakas M., et al. Exons 16 and 17 of the amyloid precursor protein gene in familial inclusion body myopathy. Ann Neurol 38 (1995) 267-269
30. Kok C., Boyt A., Gaudieri S., et al. Mitochondrial DNA variants in inclusion body myositis. Neuromuscul Disord 10 (2000) 604-611
31. Garlepp M., and Mastaglia F. Apolipoprotein E and inclusion body myositis. Ann Neurol 40 (1996) 826-828
32. Askanas V., Engel W., Mirabella M., et al. Apolipoprotein E alleles in sporadic inclusion body myositis and hereditary inclusion body myopathy. Ann Neurol 40 (1996) 264-265
33. Gossrau G., Gestrich B., Koch R., et al. Apolipoprotein E and α-1-antichymotrypsin polymorphisms in sporadic inclusion body myositis. Eur Neurol 51 (2004) 215-220
34. Harrington C., Anderson J., and Chan K. Apolipoprotein E type epsilon 4 allele frequency is not increased in patients with sporadic inclusion body myositis. Neurosci Lett 183 (1995) 35-38
35. Love S., Nicoll J., Lowe J., and Sherriff F. Apolipoprotein E allele frequencies in sporadic inclusion body myositis. Muscle Nerve 19 (1996) 1605-1607
36. Price P., Campbell W., Allcock R., et al. The genetic basis for the association of the 8.1 ancestral haplotype (A1, B8, DR3) with multiple immunopathological diseases. Immunol Rev 167 (1999) 257-274
37. Griggs R., Askanas V., DiMauro S., et al. Inclusion body myositis and myopathies. Ann Neurol 38 (1995) 705-713
38. Felice K., Relva G., and Conway S. Further observations on forearm flexor weakness in inclusion body myositis. Muscle Nerve 21 (1998) 659-661
39. Houser S., Calabrese L., and Strome M. Dysphagia in patients with inclusion body myositis. Laryngoscope 108 (1998) 1001-1005
40. Schlesinger I., Soffer D., Lossos A., Meiner Z., and Argov Z. Inclusion body myositis: atypical clinical presentations. Eur Neurol 36 (1996) 89-93
41. McKee D., Karpati G., Carpenter S., and Johnston W. Familial inclusion body myositis mimics facioscapulohumeral dystrophy. Neurology 42 (1992) 302
42. Luque F., Rosenkilde C., and Valsamis M. Inclusion body myositis presenting with dropped head syndrome. Brain Pathol 4 (1994) 568
43. Hund E., Heckl R., Goebel H., and Meinck H. Inclusion body myositis presenting with isolated erector spinae paresis. Neurology 45 (1995) 993-994
44. Lotz B., Engel A., Nishino H., Stevens J., and Litchy W. Inclusion body myositis: observations in 40 patients. Brain 112 (1989) 727-747
45. Lindberg C., Oldfors A., and Hedstrom A. Inclusion body myositis: peripheral nerve involvement: combined morphological and electrophysiological studies on peripheral nerves. J Neurol Sci 99 (1990) 327-338
46. Phillips B., Cala L., Thickbroom G., Melsom A., Zilko P., and Mastaglia F. Patterns of muscle involvement in sporadic inclusion body myositis. a clinical and MRI study. Muscle Nerve 24 (2001) 1526-1534
47. Sekul E., Chow C., and Dalakas M. Magnetic resonance imaging of the forearm as a diagnostic aid in patients with sporadic inclusion body myositis. Neurology 48 (1997) 863-866
48. Semino-Mora C., and Dalakas M. Rimmed vacuoles with β amyloid and ubiquitinated filamentous deposits in the muscles of patients with long-standing denervation (postpoliomyelitis muscular atrophy): similarities with inclusion body myositis. Hum Pathol 29 (1998) 1128-1133
49. Askanas V., Engel W., and Alvarez R. Enhanced detection of Congo-red-positive amyloid deposits in muscle fibers of inclusion body myositis and brain of Alzheimer's disease using fluorescence technique. Neurology 43 (1993) 1265-1267
50. Askanas V., Serdaroglu P., Engel W., and Alvarez R. Immunolocalization of ubiquitin in muscle biopsies of patients with inclusion body myositis and oculopharyngeal muscular dystrophy. Neurosci Lett 130 (1991) 73-76
51. Askanas V., Alvarez R., Mirabella M., and Engel W. Use of anti-neurofilament antibody to identify paired-helical filaments in inclusion-body myositis. Ann Neurol 39 (1996) 389-391
52. van der Meulen M., Hoogendijk J., Moons K., Veldman H., Badrising U., and Wokke J. Rimmed vacuoles and the added value of SMI-31 staining in diagnosing sporadic inclusion body myositis. Neuromuscul Disord 11 (2001) 447-451
53. Tawil R., and Griggs R. Inclusion body myositis. Curr Opin Rheumatol 14 (2002) 653-657
54. Dahlbom K., Lindberg C., and Oldfors A. Inclusion body myositis: morphological clues to correct diagnosis. Neuromuscul Disord 12 (2002) 853-857
55. Dalakas M. Inflammatory disorders of muscle: progress in polymyositis, dermatomyositis and inclusion body myositis. Curr Opin Neurol 17 (2004) 561-567
56. Dalakas M. Muscle biopsy findings in inflammatory myopathies. Rheum Dis Clin North Am 28 (2002) 779-798
57. Askanas V., and Engel W. Sporadic inclusion body myositis and its similarities to Alzheimer disease brain: recent approaches to diagnosis and pathogenesis, and relation to aging. Scand J Rheumatol 27 (1998) 389-405
58. Pruitt II J., Showalter C., and Engel A. Sporadic inclusion body myositis: counts of different types of abnormal fibers. Ann Neurol 39 (1996) 139-143
59. Dalakas M. The molecular and cellular pathology of inflammatory muscle diseases. Curr Opin Pharmacol 3 (2001) 300-306
60. Emslie-Smith A., Arahata K., and Engel A. Major histocompatibility complex class 1 antigen expression, immunolocalization of interferon subtypes and T-cell-mediated cytotoxicity in myopathies. Hum Pathol 20 (1989) 224-230
61. Karpati G., Pouliot Y., and Carpenter S. Expression of immunoreactive major histocompatibility complex products in human skeletal muscles. Ann Neurol 23 (1988) 64-72
62. Schmidt J., Rakocevic G., Raju R., and Dalakas M. Upregulated inducible co-stimulator (ICOS) and ICOS ligand in inclusion body myositis muscle: significance for CD8+ T cell cytotoxicity. Brain 127 (2004) 1182-1190
63. Wiendl H., Mitsdoerffer M., Schneider D., et al. Muscle fibres and cultured muscle cells express the B7.1/2-related inducible co-stimulatory molecule, ICOSL: implications for the pathogenesis of inflammatory myopathies. Brain 126 (2003) 1026-1035
64. Amemiya K., Granger R., and Dalakas M. Clonal restriction of T-cell receptor expression by infiltrating lymphocytes in inclusion body myositis persists over time: studies in repeated muscle biopsies. Brain 123 (2000) 2030-2039
65. Bender A., Behrens L., Engel A., and Hohlfeld R. T cell heterogeneity in muscle lesions of inclusion body myositis. J Neuroimmunol 84 (1998) 86-91
66. Muntzing K., Lindberg C., Moslemi A., and Oldfors A. Inclusion body myositis: clonal expansions of muscle-infiltrating T cells persist over time. Scand J Immunol 58 (2003) 195-200
67. Dimitri D., Benveniste O., Dubourg O., et al. Shared blood and muscle CD8+ T cell expansions in inclusion body myositis. Brain 129 (2006) 986-995
68. Figarella-Branger D., Civatte M., Bartoli C., and Pellissier J. Cytokines, chemokines, and cell-adhesion molecules in inflammatory myopathies. Muscle Nerve 28 (2003) 659-682
69. Lundberg I., Brengman J., and Engel A. Analysis of cytokine expression in muscle in inflammatory myopathies, Duchenne dystrophy, and non-weak controls. J Neuroimmunol 63 (1995) 9-16
70. Lepidi H., Frances V., Figarella-Branger D., Bartoli C., Machado-Baeta A., and Pellissier J. Local expression of cytokines in idiopathic inflammatory myopathies. Neuropathol Appl Neurobiol 24 (1998) 73-79
71. Raju R., and Dalakas M. Gene expression profile in the muscles of patients with inflammatory myopathies: effect of therapy with IVIg and biologic validation of clinical relevant genes. Brain 128 (2005) 1887-1896
72. Greenberg S., Sandoudou D., Haslett J., Kohane I., Kunkel L., and Beggs A. Molecular profiles of inflammatory myopathies. Neurology 59 (2002) 1170-1182
73. Koffman B., Rugiero M., and Dalakas M. Autoimmune diseases and autoantibodies associated with sporadic inclusion body myositis. Muscle Nerve 21 (1998) 115-117
74. Dalakas M., and Illa I. Common variable immunodeficiency and inclusion body myositis: a distinct myopathy mediated by natural killer cells. Ann Neurol 37 (1995) 806-810
75. Dalakas M., Illa I., Gallardo E., and Juarez C. Inclusion body myositis and paraproteinemia: incidence and immunopathologic correlations. Ann Neurol 41 (1997) 100-104
76. Ozden S., Gessain A., Gout O., and Mikol J. Sporadic inclusion body myositis in a patient with human T-cell leukemia virus type 1-associated myelopathy. Clin Infect Dis 32 (2001) 510-514
77. Ozden S., Cochet M., Mikol J., Teixeira A., Gessain A., and Pique C. Direct evidence for a chronic CD8+ T-cell-mediated immune reaction to tax within the muscle of a human T-cell leukemia/lymphoma virus type-1-infected patient with sporadic inclusion body myositis. J Virol 78 (2004) 10320-10327
78. Cupler E., Leon-Monzon M., Miller J., Semino-Mora C., Anderson T., and Dalakas M. Inclusion body myositis in HIV-1 and HTLV-1 infected patients. Brain 119 (1996) 1887-1893
79. Riggs J., Schochet Jr. S., Gutmann L., McComas C., and Rogers II J. Inclusion body myositis and chronic immune thrombocytopenia. Arch Neurol 41 (1984) 93-95
80. Williams S., Mincey B., and Calamia K. Inclusion body myositis associated with celiac sprue and idiopathic thrombocytopenic purpura. South Med J 96 (2003) 721-723
81. Kanellopoulos P., Baltoyiannis C., and Tzioufas A. Primary Sjögren's syndrome associated with inclusion body myositis. Rheumatology 41 (2002) 440-444
82. Danon M., Perurena O., Ronan S., and Manaligod J. Inclusion body myositis associated with systemic sarcoidosis. Can J Neurol Sci 13 (1986) 334-336
83. McCoy A., Bubb M., Plotz P., and Davis J. Inclusion body myositis long after dermatomyositis: a report of two cases. Clin Exp Rheumatol 17 (1999) 235-239
84. Limaye V., Scott G., Kwiatek R., and Pile K. Inclusion body myositis associated with systemic lupus erythematosus (SLE). Aust N Z J Med 30 (2000) 275-276
85. Kim S., Genth E., Krieg T., and Hunzelmann N. PM-Scl antibody positive systemic sclerosis associated with inclusion-body myositis. Rheumatol 64 (2005) 499-502
86. Yakushiji Y., Satoh J., Yukitake M., et al. Interferon beta-responsive inclusion body myositis in a hepatitis C virus carrier. Neurology 63 (2004) 587-588
87. Alexander J., and Huebner C. Hepatitis C and inclusion body myositis. Am J Gastroenterol 91 (1996) 1845-1847
88. Bouillot S., Coquet M., Ferrer X., Lagueny A., Leroy J., and Vital C. Inclusion body myositis associated with sacroidosis: a report of 3 cases. Ann Pathol 21 (2001) 334-336
89. Mastaglia F., and Phillips B. Idiopathic inflammatory myopathies: epidemiology, classification, and diagnostic criteria. Rheum Dis Clin North Am 28 (2002) 723-741
90. Cherin P., Menard D., Mouton P., et al. Macrophagic myofasciitis associated with inclusion body myositis: a report of three cases. Neuromuscul Disord 11 (2001) 452-457
91. Parissis D., Karkavelas G., Taskos N., and Milonas I. Inclusion body myositis in a patient with a presumed diagnosis of post-polio syndrome. J Neurol 250 (2003) 619-621
92. Murata K., and Dalakas M. Expression of the co-stimulatory molecule BB-1, the ligands CTLA-4 and CD28, and their mRNA in inflammatory myopathies. Am J Pathol 155 (1999) 453-460
93. Goebels N., Michaelis D., Engelhardt M., et al. Differential expression of perforin in muscle-infiltrating T cells in polymyositis and dermatomyositis. J Clin Invest 97 (1996) 2905-2910
94. Nagaraju K., Casciola-Rosen L., Lundberg I., et al. Activation of the endoplasmic reticulum stress response in autoimmune myositis. Arthritis Rheum 52 (2005) 1824-1835
95. Vattemi G., Engel W., McFerrin J., and Askanas V. Endoplasmic reticulum stress and unfolded protein response in inclusion body myositis muscle. Am J Pathol 164 (2004) 1-7
96. Zhang K., and Kaufman R. The unfolded protein response: a stress signaling pathway critical for health and disease. Neurology 66 suppl 1 (2006) S102-S109
97. Askanas V., and Engel W. Molecular pathology and pathogenesis of inclusion body myositis. Microsc Res Tech 67 (2005) 114-120
98. Yang C., Askanas V., Engel W., and Alvarez R. Immunolocalization of transcription factor NF-kB in inclusion body myositis muscle and at normal human neuromuscular junctions. Neurosci Lett 254 (1998) 77-80
99. Nagaraju K., Raben N., Loeffler L., et al. Conditional upregulation of MHC class I in skeletal muscle leads to self-sustaining autoimmune myositis and myositis-specific autoantibodies. Proc Natl Acad Sci USA 97 (2000) 9209-9214
100. Greenberg S., Bradshaw E., Pinkus J., et al. Plasma cells in muscle in inclusion body myositis and polymyositis. Neurology 65 (2005) 1782-1787
101. Barohn R., Amato A., Sahenk Z., Kissel J., and Mendell J. Inclusion body myositis: explanation for poor response to immunosuppressive therapy. Neurology 45 (1995) 1302-1304
102. Askanas V., McFerrin J., Alvarez R., Baque S., and Engel W. βAPP gene transfer into cultured human muscle induces inclusion body myositis aspects. Neuroreport 8 (1997) 2155-2158
103. Fukuchi K., Pham D., Hart M., Li L., and Lindsey J. Amyloid-beta deposition in skeletal muscle of transgenic mice: possible model of inclusion body myopathy. Am J Pathol 153 (1998) 1687-1693
104. Jin L., Hearn M., Ogburn C., et al. Transgenic mice overexpressing the C-99 fragment of βPP with an α-secretase site mutation develop a myopathy similar to human inclusion body myositis. Am J Pathol 153 (1998) 1679-1686
105. Sugarman M., Yamasaki T., Oddo S., et al. Inclusion body myositis-like phenotype induced by transgenic overexpression of βAPP in skeletal muscle. Proc Natl Acad Sci USA 99 (2002) 6334-6339
106. Kitazawa M., Green K., Caccamo A., and LaFerla F. Genetically augmenting Aβ42 levels in skeletal muscle exacerbates inclusion body myositis-like pathology and motor deficits in transgenic mice. Am J Pathol 168 (2006) 1986-1997
107. Fratta P., Engel W., McFerrin J., Davies K., Lin S., and Askanas V. Proteasome inhibition and aggresome formation in sporadic inclusion body myositis and in amyloid-β precursor protein-overexpressing cultured human muscle fibers. Am J Pathol 167 (2005) 517-526
108. Askanas V., and Engel W. Sporadic inclusion body myositis and hereditary inclusion body myopathies: diseases of oxidative stress and aging?. Arch Neurol 55 (1998) 915-920
109. Askanas V., Sarkozi E., Alvarez R., McFerrin J., Siddique T., and Engel W. SOD1 gene and protein in vacuolated muscle fibers of s-IBM, h-IBM, and in cultured human muscle after bAPP gene transfer. Neurology 46 (1996) 487
110. Yang C., Alvarez R., Engel W., and Askanas V. Increase of nitric oxide synthases and nitrotyrosine in inclusion-body myositis. Neuroreport 8 (1996) 153-158
111. Tateyama M., Takeda A., Onodera Y., et al. Oxidative stress and predominant Aβ42(43) deposition in myopathies with rimmed vacuoles. Acta Neuropathologica 105 (2003) 581-585
112. Broccolini A., Engel W., Alvarez R., and Askanas V. Redox factor-1 in muscle biopsies of patients with inclusion-body myositis. Neurosci Lett 287 (2000) 1-4
113. Butterfield D. β-Amyloid-associated free radical oxidative stress and neurotoxicity: implications for Alzheimer's disease. Chem Res Toxicol 10 (1997) 495-506
114. Paciello O., Wojcik S., Engel W., McFerrin J., and Askanas V. Parkin and its association with α-synuclein and AβPP in inclusion body myositis and AβPP-overexpressing cultured human muscle fibers. Acta Myol 25 (2006) 13-22
115. Varshavsky A. The ubiquitin system. Trends Biochem Sci 22 (1997) 383-387
116. Fratta P., Engel W., Van Leeuwen F., Hol E., Vattemi G., and Askanas V. Mutant ubiquitin UBB+1 is accumulated in sporadic inclusion-body myositis muscle fibers. Neurology 63 (2004) 1114-1117
117. van Leeuwen F., Fischer D., Kamel D., et al. Molecular misreading: a new type of transcript mutation expressed during aging. Neurobiol Aging 21 (2000) 879-891
118. Askanas V., and Engel W. Inclusion body myositis: newest concepts of pathogenesis and relation to aging and Alzheimer disease. J Neuropathol Exp Neurol 60 (2001) 1-14
119. De Bleecker J., Engel A., and Ertl B. Myofibrillar myopathy with abnormal foci of desmin positivity: II. immunocytochemical analysis reveals accumulation of multiple other proteins. J Neuropathol Exp Neurol 55 (1996) 563-577
120. Ferrer I., Martin B., Castano J., Lucas J., Moreno D., and Olive M. Proteasomal expression, induction of immunoproteasome subunits, and local MHC class I presentation in myofibrillar myopathy and inclusion body myositis. J Neuropathol Exp Neurol 63 (2004) 484-498
121. Ferrer I., Carmona M., Blanco R., Moreno D., Torrejon-Escribano B., and Olive M. Involvement of clusterin and the aggresome in abnormal protein deposits in myofibrillar myopathies and inclusion body myositis. Brain Pathol 15 (2005) 101-108
122. Askanas V., and Engel W. Newest approaches to diagnosis and pathogenesis of sporadic inclusion body myositis and hereditary inclusion body myopathies, including molecular-pathologic similarities to Alzheimer disease. In: Askanas V., Serratrice G., and Engel W. (Eds). Inclusion-body myositis and myopathies (1998), Cambridge University, Cambridge 3-78
123. Schmidt J., Raju R., Salajegheh M., Rakocevic G., Voss J., and Dalakas M. Distinct interplay between inflammatory and degeneration-associated molecules in sporadic IBM. Neurology 64 (2005) A331-A338
124. Banwell B., and Engel A. αB-crystallin immunolocalization yields new insights into inclusion body myositis. Neurology 54 (2000) 1033-1041
125. Wojcik S., Engel W., McFerrin J., Paciello O., and Askanas V. AβPP-overexpression and proteasome inhibition increase αB-crystallin in cultured human muscle: relevance to inclusion body myositis. Neuromuscul Disord 16 (2006) 839-844
126. Peng A., Koffman B., Malley J., and Dalakas M. Disease progression in sporadic inclusion body myositis: observations in 78 patients. Neurology 55 (2000) 296-298
127. Rose M., McDermott M., Thornton C., Palenski C., Martens W., and Griggs R. A prospective natural history study of inclusion body myositis: implications for clinical trials. Neurology 57 (2001) 548-550
128. Griggs R. The current status of treatment for inclusion body myositis. Neurology 66 suppl 1 (2006) S30-S32
129. Dalakas M. Therapeutic targets in patients with inflammatory myopathies: present approaches and a look to the future. Neuromuscul Disord 16 (2006) 223-236
130. Mastaglia F., Garlepp M., Phillips B., and Zilko P. Inflammatory myopathies: clinical, diagnostic and therapeutic aspects. Muscle Nerve 27 (2003) 407-425
131. Badrising U., Maat-Schieman M., Ferrari M., et al. Comparison of weakness progression in inclusion body myositis during treatment with methotrexate or placebo. Ann Neurol 51 (2002) 369-372
132. Leff R., Miller F., Hicks J., Fraser D., and Plotz P. The treatment of inclusion body myositis: a retrospective review and a randomized, prospective trial of immunosuppressive therapy. Medicine 72 (1993) 225-235
133. Mowzoon N., Sussman A., and Bradley W. Mycophenolate (CellCept) treatment of myasthenia gravis, chronic inflammatory polyneuropathy and inclusion body myositis. J Neurol Sci 185 (2001) 119-122
134. Soueidan S., and Dalakas M. Treatment of inclusion body myositis with high-dose intravenous immunoglobulin. Neurology 43 (1993) 876-879
135. Amato A., Barohn R., Jackson C., Pappert E., Sahenk Z., and Kissel J. Inclusion body myositis: treatment with intravenous immunoglobulin. Neurology 444 (1994) 1516-1518
136. Dalakas M., Sonies B., Dambrosia J., Sekul E., Cupler E., and Sivakumar K. Treatment of inclusion body myositis with IVIg: a double-blind, placebo-controlled study. Neurology 48 (1997) 712-716
137. Walter M., Lochmuller H., Toepfer M., et al. High-dose immunoglobulin therapy in sporadic inclusion body myositis: a double-blind, placebo-controlled study. J Neurol 247 (2000) 22-28
138. Cherin P., Pelletier S., Teixeira A., et al. Intravenous immunoglobulin for dysphagia of inclusion body myositis. Neurology 58 (2002) 326
139. Lindberg C., Trysberg E., Tarkowski A., and Oldfors A. Anti-T-lymphocyte globulin treatment in inclusion body myositis. Neurology 61 (2003) 260-262
140. Group T. Randomized pilot trial of beta INF1a (Avonex) in patients with inclusion body myositis. Neurology 57 (2001) 1566-1570
141. Group T. Randomized pilot trial of high-dose βINF-1a in patients with inclusion body myositis. Neurology 63 (2004) 718-720
142. Barohn R., Herbelin L., Kissel J., et al. Pilot trial of etanercept in the treatment of inclusion body myositis. Neurology 66 (2006) S123-S124
143. Rutkove S., Parker R., Nardin R., et al. A pilot randomized trial of oxandrolone in inclusion body myositis. Neurology 58 (2002) 1081-1087
144. Darrow D., Hoffman H., Barnes G., and Wiley C. Management of dysphagia in inclusion body myositis. Arch Otolaryngol Head Neck Surg 118 (1992) 313-317
145. Liu L., Tarnopolsky M., and Armstrong D. Injection of botulinum toxic A to the upper esophageal sphincter for oropharyngeal dysphagia in two patients with inclusion body myositis. Can J Gastroenterol 18 (2004) 397-399
146. Arnardottir S., Alexanderson H., Lundberg I., and Borg K. Sporadic inclusion body myositis: pilot study on the effects of a home exercise program on muscle function, histopathology and inflammatory reaction. J Rehabil Med 35 (2003) 31-35
147. Heikkila S., Vittanen J., and Kautianen H. Rehabilitation in myositis. Physiotherapy 87 (2001) 301-309
148. Spector S., Lemmer J., Koffman B., et al. Safety and efficacy of strength training in patients with sporadic inclusion body myositis. Muscle Nerve 20 (1997) 1242-1248
149. Waclawik A., and Rao V. Effective treatment of severe finger flexion weakness in inclusion body myositis using tendon transfers. J Clin Neuromuscul Dis 4 (2002) 31-32
150. Glabe C., and Kayed R. Common structure and toxic function of amyloid oligomers implies a common mechanism of pathogenesis. Neurology 66 (2006) S74-S78
151. Steinman L. Controlling autoimmunity in sporadic inclusion body myositis. Neurology 66 (2006) S56-S58
152. Jaworska-Wilczynska M., Wilczynski G., Engel W., Strickland D., Weisgraber K., and Askanas V. Three lipoprotein receptors and cholesterol in inclusion body myositis muscle. Neurology 58 (2002) 438-445
153. Needham M., Fabian V., Knezevic W., Panegyres P., Zilko P., and Mastaglia F. Progressive myopathy with up-regulation of MHC-I associated with statin therapy. Neuromuscul Disord 17 (2007) 194-200